Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia. Current pharmacological treatment

M Jønler1, M Riehmann, R C Bruskewitz

  • 1Department of Urology, University of Wisconsin-Madison.

Drugs
|January 1, 1994
PubMed
Summary

Pharmacological treatments for benign prostatic hyperplasia (BPH) include alpha-blockers and androgen suppressors. Selective alpha-1 blockers and finasteride offer effective symptom relief with manageable side effects for BPH patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Economics of transurethral thermotherapy of the prostate.

World journal of urology·2002
Same author

Correlates of urinary symptom scores in men.

American journal of public health·1999
Same author

The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study.

The Journal of urology·1999
Same author

Impact of drug therapy on benign prostatic hyperplasia-specific quality of life.

Urology·1999
Same author

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

Urology·1999

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Pharmacological treatment is a well-established modality for symptomatic benign prostatic hyperplasia (BPH).
  • Current approaches involve alpha-adrenoreceptor blockade and androgen suppression.
  • Drug therapy is suitable for patients with mild to moderate BPH symptoms without surgical indications.

Purpose of the Study:

  • To review established and emerging pharmacological treatments for benign prostatic hyperplasia (BPH).
  • To compare the efficacy and side effect profiles of different drug classes.
  • To discuss potential future therapeutic strategies for BPH.

Main Methods:

  • Review of pharmacological agents for BPH, including alpha-receptor blockers and antiandrogens.
  • Discussion of drug efficacy, onset of action, and adverse effect profiles.

Related Experiment Videos

  • Consideration of combination therapy and drugs under clinical investigation.

    • Main Results:

    • Alpha-receptor blockers improve urinary symptoms and flow rates within weeks; selective alpha-1 blockers are preferred due to fewer side effects.
    • Finasteride effectively reduces prostate volume and obstruction symptoms with good tolerability, though maximum effect requires 6-12 months.
    • Other antiandrogens (GnRH agonists, progestogens, flutamide) have significant adverse effects.

    Conclusions:

    • Selective alpha-1 blockers and finasteride are key pharmacological treatments for BPH.
    • Combination therapy with alpha-1 blockers and finasteride represents a promising future approach.
    • Careful patient selection and consideration of side effect profiles are crucial for effective BPH management.